Brian Solow, MD

Employers know that managing chronic conditions and preventing drug-drug interactions can boost productivity

Brian Solow, MD

There’s no denying that the medication therapy management programs (MTMPs) mandated for Medicare Part D plans have been beneficial for seniors, producing positive results that help seniors live healthier lives. The basic principles of these programs are transferable to commercial populations, providing employers with innovative programs to better manage increasing medical and prescription drug costs.

The statistics continue to alarm. In a 2005 Commonwealth Fund survey of working Americans ages 19 to 64, two thirds missed one or more days of work because of their own health problems or those of a family member.

A well-designed and executed MTMP can help employees achieve the highest quality of life possible and a higher level of productivity by helping ensure that they use their drugs safely and appropriately.

Tracking claims

Leading PBMs are at the forefront of promoting safe drug utilization to prevent adverse drug reactions (ADRs) and reduce health care costs with drug interaction detection programs. These programs track all prescription claims for a member from any pharmacy and any doctor in real time, and specifically target members who fill a drug that interacts with a previously filled medication prescribed by a different doctor.

Other examples of MTMP that have evolved from the senior marketplace include:

  • Polypharmacy programs: These programs are member- and provider-based interventions designed to promote safe and appropriate medication use. The two-phase effort first notifies providers of members with polypharmacy cases. The second phase is a direct-to-members outreach to those who continue to have polypharmacy issues after the provider mailings.
  • ACEI/ARB initiatives in disease management: These programs are designed to optimize the use of ACEI/ARB therapy in patients with DM and HTN and/or nephropathy by targeting providers of members with the above disease states and no fill history for ACEI/ARB therapy.
  • Refill-reminder programs: Refill reminder programs offer member-based interventions that target MTMP enrollees who have been identified as non-adherent with select oral maintenance medications. The objectives of the programs are to promote patient awareness of the importance of medication adherence, improve adherence of commonly prescribed maintenance medications, and reduce the number of missed or delinquent fills of maintenance medications.

Employers have recognized that their employees’ health plays a direct role in their day-to-day productivity. More and more, they are looking to their PBMs for innovative programs that will manage their increasing medical and prescription drug costs. MTMPs have proven track records and have been shown to benefit employees of all ages. By helping employees manage their illnesses through such programs, employers help employees improve the quality of their lives, improve productivity in the workplace, and reduce health care costs by avoiding unnecessary hospitalizations and ER visits.

Brian K. Solow, MD, is vice president and senior medical director for clinical services at Prescription Solutions, a UnitedHealth Group company and a PBM that manages the drug benefit of commercial, Medicare, and governmental health plans, as well as employers, union trusts, and third-party administrators.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.